8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
Genmab A/S (GMAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 12,925,578 | $346,793,258 | -11% | 1.46% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 7,967,836 | $213,777,040 | +14% | 4.37% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 4,975,324 | $133,487,943 | -1% | 0.07% |
| 4. | Renaissance Technologies Jim Simons | 4,414,550 | $118,442,377 | +27% | 0.19% |
| 5. | Deep Track Capital David Kroin | 3,663,250 | $98,284,998 | 1.61% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,557,149 | $294,360,189 | 0.1% | |
| 2. | 4,536,565 | $121,716,030 | 0% | |
| 3. | 3,231,601 | $86,704,217 | 0.89% | |
| 4. | 2,461,342 | $66,037,805 | 0.05% | |
| 5. | 2,339,432 | $62,766,961 | 0.05% |
News See All
Genmab (GMAB) Rated Outperform on Oncology Pipeline
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook
TheFly reported on April 22 that The Goldman Sachs Group raised its rating on GMAB from Neutral to Buy and set a price target of $30.50.
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
15 Large Cap Stocks Under $30 With Huge Upside Potential
On March 20, Caroline Woods from The Street sat down with Mo Haghbin, Managing Director at ProShares, to break down where the money is actually going amid a market dealing with rising geopolitical tensions...
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales
Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion.
10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years
On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.
Genmab A/S (NASDAQ:GMAB) Q4 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab Full Year 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded.
10 High Growth International Stocks to Buy Now
On February 10, Peter Boockvar, Chief Investment Officer at BFG Wealth Partners, appeared on a CNBC television interview.
Hedge Fund Resource Center